Výsledky vyhledávání - "Jenny Middleton"

Akademický článek

AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models

Autor: Stephen M. Shaw, Jenny Middleton, Kim Wigglesworth, Amber Charlemagne, Oliver Schulz, Melanie S. Glossop, Giles F. Whalen, Robert Old, Mike Westby, Chris Pickford, Rinat Tabakman, Irit Carmi-Levy, Abi Vainstein, Ella Sorani, Arik A. Zur, Sascha A. Kristian

Publikováno v: Cancer Cell International, Vol 19, Iss 1, Pp 1-19 (2019)

Abstract Background Treatments that generate T cell-mediated immunity to a patient’s unique neoantigens are the current holy grail of cancer immunotherapy. In particular, treatments that do not require cumbersome and individualized ex vivo processi

Externí odkaz: https://doaj.org/article/440a5a0ba0874d0aa71454cddd24f71c

Zobrazit plný text záznamu

Plný text ve formátu HTML

AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models

Autor: Abi Vainstein, Arik A. Zur, Ella Sorani, Giles F. Whalen, Jenny Middleton, Chris Pickford, Melanie S. Glossop, Robert Old, Oliver Schulz, Sascha A. Kristian, Irit Carmi-Levy, Amber Charlemagne, Mike Westby, Rinat Tabakman, Kim Wigglesworth, Stephen M. Shaw

Publikováno v: Cancer Cell International, Vol 19, Iss 1, Pp 1-19 (2019)
Cancer Cell International

BackgroundTreatments that generate T cell-mediated immunity to a patient’s unique neoantigens are the current holy grail of cancer immunotherapy. In particular, treatments that do not require cumbersome and individualized ex vivo processing or manu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4a18846f7bb9b2696a1417608b07aba
https://doi.org/10.1186/s12935-019-1059-8

Zobrazit plný text záznamu

Intratumoral administration of the alpha-Gal glycolipid AGI-134 to induce tumor regression in a mouse model of melanoma

Autor: Jenny Middleton, Ella Sorani, Abi Vainstein Haras, Rinat Tabakman, Kim Wigglesworth, Sascha A. Kristian, Irit Carmi Levy, Stephen M. Shaw

Publikováno v: Journal of Clinical Oncology. 36:68-68

68 Background: AGI-134 is a fully synthetic alpha-Gal glycolipid for intratumoral (i.t.) treatment of solid tumors to induce a patient-specific anti-tumor immune response. AGI-134 recruits pre-existing anti-Gal antibodies to the injected lesion, lead

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f464f0aa1f3cf252be6ca540947a44aa
https://doi.org/10.1200/jco.2018.36.5_suppl.68

Zobrazit plný text záznamu

Abstract 616: The novel α-Gal-based immunotherapy AGI-134 invokes CD8+ T cell-mediated immunity by driving tumor cell destruction, phagocytosis and tumor-associated antigen cross-presentation via multiple antibody-mediated effector functions

Autor: Sascha A. Kristian, Jenny Middleton, Amber Charlemagne, Oliver Schulz, Stephen M. Shaw

Publikováno v: Cancer Research. 77:616-616

Background: AGI-134 is a fully synthetic α-Gal (Galα1-3Galβ1-4GlcNAc-R) glycolipid that is being developed for the treatment of solid tumors. The α-Gal epitope is not expressed in humans, who, as a result of constant antigenic stimulation by α-G

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::14f7022d0a27521c171b4aca52124706
https://doi.org/10.1158/1538-7445.am2017-616

Zobrazit plný text záznamu

Abstract 4862: AGI-134: a fully synthetic alpha-Gal glycolipid that prevents the development of distal lesions and is synergistic with an anti-PD-1 antibody in a mouse melanoma model

Autor: Jenny Middleton, Mel Glossop, Sascha A. Kristian, Mike Westby, Stephen Shaw, Kim Wigglesworth, Giles F. Whalen, Robert Old, Chris Pickford

Publikováno v: Cancer Research. 76:4862-4862

Background: AGI-134 is a fully synthetic glycolipid, composed of an alpha-Gal (Galá1-3Galâ1-4GlcNAc-R) sugar epitope attached via a linker to a lipid tail. Natural antibodies to the alpha-Gal epitope are responsible for the hyperacute rejection of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e6b2166e959129999b984295c2483f46
https://doi.org/10.1158/1538-7445.am2016-4862

Zobrazit plný text záznamu

AGI-134, a fully synthetic α-Gal-based cancer immunotherapy: Synergy with an anti-PD-1 antibody and pre-clinical pharmacokinetic and toxicity profiles

Autor: Jenny Middleton, Kim Wigglesworth, Stephen M. Shaw, Chris Pickford, Robert Old, Mike Westby, Giles F. Whalen, Uri Galili, Melanie S. Glossop, Sascha A. Kristian

Publikováno v: Journal of Clinical Oncology. 34:3083-3083

3083Background: Unlike virtually all non-primate mammals, humans lack α-Gal (Gal-α-1,3-Gal-β-1,4-GlcNAc) epitopes and produce antibodies against α-Gal-positive antigens. Anti-α-Gal (anti-Gal) antibodies are among the most abundant antibodies in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3a3401bb53c59970b459d5bfbe2650f1
https://doi.org/10.1200/jco.2016.34.15_suppl.3083

Zobrazit plný text záznamu

Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action

Autor: David C. Pryde, Chris Pickford, Paul Targett-Adams, Helen Lavender, Mike Westby, Amy Palmer, Stephen M. Shaw, Tram T. Tran, Florian Wakenhut, Blanda Luzia Christa Stammen, Jenny Middleton, Emily J. S. Graham, Philip Brain, Lyn H. Jones

Publikováno v: Journal of virology. 85(13)

The current standard of care for hepatitis C virus (HCV)-infected patients consists of lengthy treatment with interferon and ribavirin. To increase the effectiveness of HCV therapy, future regimens will incorporate multiple direct-acting antiviral (D

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1845a178119fe604a8bc37084ab3fb6d
https://pubmed.ncbi.nlm.nih.gov/21507963

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání